- Home
- ANAB vs SYRE Comparison
ANAB vs SYRE Comparison
Compare ANAB & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- SYRE
- Stock Information
- Founded
- ANAB 2005
- SYRE 2013
- Country
- ANAB United States
- SYRE United States
- Employees
- ANAB N/A
- SYRE N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- ANAB Health Care
- SYRE Health Care
- Exchange
- ANAB Nasdaq
- SYRE Nasdaq
- Market Cap
- ANAB 1.0B
- SYRE 1.1B
- IPO Year
- ANAB 2017
- SYRE 2016
- Fundamental
- Price
- ANAB $38.47
- SYRE $22.50
- Analyst Decision
- ANAB Buy
- SYRE Strong Buy
- Analyst Count
- ANAB 12
- SYRE 5
- Target Price
- ANAB $63.30
- SYRE $55.75
- AVG Volume (30 Days)
- ANAB 364.4K
- SYRE 1.3M
- Earning Date
- ANAB 11-04-2025
- SYRE 11-04-2025
- Dividend Yield
- ANAB N/A
- SYRE N/A
- EPS Growth
- ANAB N/A
- SYRE N/A
- EPS
- ANAB N/A
- SYRE N/A
- Revenue
- ANAB $169,467,000.00
- SYRE N/A
- Revenue This Year
- ANAB $37.52
- SYRE N/A
- Revenue Next Year
- ANAB N/A
- SYRE N/A
- P/E Ratio
- ANAB N/A
- SYRE N/A
- Revenue Growth
- ANAB 196.42
- SYRE N/A
- 52 Week Low
- ANAB $12.21
- SYRE $10.91
- 52 Week High
- ANAB $40.96
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- ANAB 72.78
- SYRE 55.91
- Support Level
- ANAB $34.22
- SYRE $22.48
- Resistance Level
- ANAB $37.08
- SYRE $25.06
- Average True Range (ATR)
- ANAB 2.03
- SYRE 1.19
- MACD
- ANAB -0.18
- SYRE -0.29
- Stochastic Oscillator
- ANAB 68.07
- SYRE 20.79
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.